Updated on 08/01/2016 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 6.1 - List of excipients
-
Change to section 10 - Date of revision of the text
|
| Date of revision of text on the SPC: 18-Dec-2015 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
In section 6.1, the spelling of sulphate has changed to sulfate.
In section 10, the date of revision has changed to December
|
|
Updated on 18/12/2015 and displayed until 08/01/2016
|
Reasons for adding or updating:
|
-
Change to section 3 - Pharmaceutical form
-
Change to section 10 - Date of revision of the text
|
| Date of revision of text on the SPC: 31-Mar-2015 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
In section 10, the date of revision has been updated to March 2015.
In section 3, The following text has been removed: debossed on both faces with ‘ANADIN’
the following text has been added:
The tablets have ‘325/15’ embossed on both sides.
|
|
Updated on 20/08/2014 and displayed until 18/12/2015
|
Reasons for adding or updating:
|
-
Change to section 1 - Name of medicinal product
-
Change to section 2 - Qualitative and quantitative composition
-
Change to section 4.4 - Special warnings and precautions for use
-
Change to section 4.6 - Pregnancy and lactation
-
Change to Section 4.8 – Undesirable effects - how to report a side effect
-
Change to section 5.1 - Pharmacodynamic properties
-
Change to section 5.2 - Pharmacokinetic properties
-
Change to section 6 - Pharmaceutical particulars
-
Change to section 6.1 - List of excipients
-
Change to section 8 - MA number
-
Change to section 10 - Date of revision of the text
|
| Date of revision of text on the SPC: 11-Aug-2014 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
Quinine Sulphate has been reclassified as an excipient (rather than active ingredient). This has impacted the following sections:
1; 2; 4.6; 5.1; 5.2; 6.1
In section 4.4, the following text has been added:
In patients suffering from severe glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, aspirin is known to rarely cause haemolytic anaemia.
The following text has been removed:
As NSAIDs can interfere with platelet function , they should be used with caution in patients with intercranial haemorrhage and bleeding diathesis.
In 4.6, the title has been updated to match QRD template, and sub headings 'Pregnancy', 'Breast feeding' and 'Fertility' have been added. The following text has been added:
Fertility
If acetylsalicylic acid is used by a woman attempting to conceive the dose should be kept as low as possible and the duration of use as short as possible. Animal studies have shown an increased risk of pre -implantation loss and various malformations including cardiovascular.
In 4.8, the undesirable effects 'anaemia, aplastic anaemia, pancytopenia' have been added. The HPRA reporting information has also been added.
The title of 6.6. has been updated to match QRD wording.
In section 8, MA number has been reformatted, with zeros added: PA0822/165/001
In section 10, the date of revision has been updated from December 2012 to August 2014.
|
|
Updated on 19/12/2012 and displayed until 20/08/2014
|
Reasons for adding or updating:
|
-
Change to marketing authorisation holder
|
| Date of revision of text on the SPC: 07-Dec-2012 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
MAH is Pfizer Healthcare Ireland, Citywest Business Campus, Dublin 24.
PA 822/165/1.
|
|
Updated on 20/06/2011 and displayed until 19/12/2012
|
Reasons for adding or updating:
|
-
Change to section 4.6 - Pregnancy and lactation
-
Change to section 4.8 - Undesirable effects
-
Change to section 4.9 - Overdose
-
Change to section 5.1 - Pharmacodynamic properties
-
Change to section 5.2 - Pharmacokinetic properties
-
Change to section 4.2 - Posology and method of administration
-
Change to section 4.3 - Contraindications
-
Change to section 4.4 - Special warnings and precautions for use
-
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
|
| Date of revision of text on the SPC: 14-Feb-2011 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
4.2 Posology and Method of Administration
Adults and Adolescents over 16 years: Take 2 tablets every 4 hours if necessary. Do not exceed 12 tablets in any 24 hour period.
Take 2 tablets every 4 hours if necessary. Do not exceed 12 tablets in any 24 hour period.
4.3 Contra-indications
Patients with a history of hypersensitivity reactions (e.g. bronchospasm, rhinitis, urticaria) in response to Anadin Analgesic Film-coated Tablets, aspirin or other non-steroidal anti-inflammatory drugs or any of the other constituents.
Children and adolescents under 16 years.
Breast-feeding.
Last-trimester of pregnancy.
Concurrent anti-coagulant therapy.
Patients with severe renal failure.
Intake of more than 15mg methotrexate per week.
4.4 Special Warnings and Precautions for Use
As NSAIDs can interfere with platelet function, they should be used with caution in patients with intracranial haemorrhage and bleeding diathesis.
4.5 Interactions with other medicinal products and other forms of interactions
Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the
effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These
interactions should be considered in patients taking Anadin Analgesic Film-coated Tablets concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.
4.6 Pregnancy and Lactation
Acetylsalicylic acid should not be used during the first and second trimester of pregnancy unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimesters, the dose should be kept as low as possible and the duration of use as short as possible. It has been suggested in epidemiological studies that prostaglandin synthesis inhibition in early pregnancy is associated with an increased risk of miscarriage, cardiac malformation and gastroschisis. Animal studies have shown an increased risk of pre and post-implantation loss and various malformations including cardiovascular.
In the third trimester, there is also the risk of cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension) and renal dysfunction.
4.9 Overdose
Salicylate poisoning is usually associated with plasma concentrations > 350 mg/l (2.5 mmol/l). Most adult deaths occur in patients whose concentrations exceed 700 mg/l (5.1 mmol/L). Single dose less than 100mg/kg are unlikely to cause serious poisoning.
Aspirin
Common features include vomiting, dehydration, tinnitus, vertigo, deafness, sweating, warm extremities with bounding pulses, increased respiratory rate and hyperventilation. Some degree of acid-base disturbance is present in most cases. A mixed respiratory alkalosis and metabolic acidosis with normal or high arterial pH (normal or reduced hydrogen ion concentration) is usual in adults and children over the age of four years old. In children aged four years or less, a dominant metabolic acidosis with low arterial pH (raised hydrogen ion concentration) is common. Acidosis may increase salicylate transfer across the blood brain barrier. Uncommon features include haematemesis, hyperpyrexia, hypoglycaemia, hypokalaemia, thrombocytopaenia, increased INR/PTR, intravascular coagulation, renal failure and non-cardiac pulmonary oedema.
Central nervous system features including confusion, disorientation, coma and convulsions are more common in children than adults.
Caffeine
Common features include CNS stimulation; anxiety, nervousness, restlessness, insomnia, excitement, muscle twitching, confusion, convulsions. Cardiac Symptoms include tachycardia, cardiac arrhythmia. Gastric symptoms include abdominal or stomach pains.
Other symptoms of overdosage, associated with the caffeine component, include diuresis and facial flushing.
Management
Aspirin
Give activated charcoal if an adult presents within one hour of ingestion of more than 250 mg/kg. The plasma salicylate concentration should be measured, although the severity of poisoning cannot be determined from this alone and the clinical and biochemical features must be taken into account. Elimination is increased by urinary alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate.
The urine pH should be monitored. Correct metabolic acidosis with intraveneous 8.4
% sodium bicarbonate (first check serum potassium). Forced diuresis should not be used since it does not enhance salicylate excretion and may cause pulmonary oedema.
Haemodialysis is the treatment of choice for severe poisoning and should be considered in patients with plasma salicylate concentrations > 700 mg/l (5.1 mmol/l), or lower concentrations associated with severe clinical or metabolic features. Patients under 10 years or over 70 years have increased risk of salicylate toxicity and may
require dialysis at an earlier stage.
Caffeine
Treatment of caffeine overdose is primarily symptomatic and supportive. Diuresis
should be treated by maintaining fluid and electrolyte balance and CNS symptoms
can be controlled by intravenous administration of diazepam.
5.1 Pharmacodynamic Properties
ATC code: N02BE51
Pharmacotherapeutic group: Other analgesics and antipyretics
Mechanisms of action/effect
Salicylates inhibit the activity of the enzyme cyclo-oxygenase to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Although many of the therapeutic effects may result from inhibition of prostaglandin synthesis (and consequent reduction of prostaglandin activity) in various tissues, other actions may also contribute significantly to the therapeutic effects.
Analgesic
Produces analgesia through a peripheral action by blocking pain impulse generation and via a central action, possibly in the hypothalamus.
Anti-inflammatory (Nonsteriodal)
Exact mechanisms have not been determined. Salicylates may act peripherally in inflamed tissue probably by inhibiting the synthesis of prostaglandins and possibly by inhibiting the synthesis and/or actions of other mediators of the inflammatory response.
Antipyretic
May produce antipyresis by acting centrally on the hypothalamic heat-regulating centre to produce peripheral vasodilation resulting in increased cutaneous blood flow, sweating and heat loss.
Caffeine
Mechanisms of action/effect
Central nervous system stimulant - caffeine stimulates all levels of the CNS, although its cortical effects are milder and of shorter duration than those of amphetamines.
Analgesia adjunct
Caffeine constricts cerebral vasculature with an accompanying decrease in the cerebral blood flow and in the oxygen tension of the brain. It is believed that caffeine helps to relieve headache by providing more rapid onset of action and/or enhancing pain relief with lower doses of analgesic. Recent studies with ergotamine indicate that the enhancement of effect by the addition of caffeine may also be due to improved gastrointestinal absorption of ergotamine when administered with caffeine.
5.2 Pharmacokinetic Properties
Caffeine is excreted in the urine. The major metabolites are 1-methylxanthine, 7-methylxanthine and 1,7- dimethylxanthine (paraxanthine). Minor metabolites include 1-methyluric acid, and 5-acetylamino-6 formylamino 3-methyluracil (AMFU).
In adults, marked individual variability in the rate of elimination occurs. The mean plasma elimination half life is 4.9 hours with a range of 1.9 - 12.2 hours. Caffeine distributes into all body fluids. The mean plasma protein binding of caffeine is 35%.
|
|
Updated on 10/08/2010 and displayed until 20/06/2011
|
Reasons for adding or updating:
|
-
Change to marketing authorisation holder
|
| Date of revision of text on the SPC: 30-Jun-2010 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
|
7. MARKETING AUTHORISATION HOLDER
Pfizer Consumer Healthcare Ltd
Ramsgate Road, Sandwich
Kent CT13 9NJ
United Kingdom
(Formally Wyeth Consumer Healthcare)
|
|
Updated on 09/06/2010 and displayed until 10/08/2010
|
Reasons for adding or updating:
|
-
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
-
Change to section 4.8 - Undesirable effects
-
Change to section 5.1 - Pharmacodynamic properties
-
Change to section 9 - Date of renewal of authorisation
-
Change to section 10 - Date of revision of the text
-
Change to product name
-
Change to section 4.4 - Special warnings and precautions for use
|
| Date of revision of text on the SPC: 21-May-2010 |
| Legal Category: Supply through general sale |
Free-text change information supplied by the pharmaceutical company
|
1. Renewal completed and the product name was changed in line with EU guidance.
2. Product information brought in line with EU warnings on disturbances in female fertility, cardiovascular and G.I. safety and serious skin reactions. Thrombotic risks.
3. Interactions of aspirin and ibuprofen.
|
|
Updated on 12/12/2006 and displayed until 09/06/2010
|
Reasons for adding or updating:
|
-
Change to section 6.3 - Shelf life
|
| Date of revision of text on the SPC: 12/2006 |
| Legal Category: general sale |
Free-text change information supplied by the pharmaceutical company
|
Amend section 6.3
Shelf -life increased to 36 months
|
|
Updated on 31/03/2005 and displayed until 12/12/2006
|
Reasons for adding or updating:
|
-
Change to section 3 - Pharmaceutical form
|
|
Updated on 17/12/2004 and displayed until 31/03/2005
|
Reasons for adding or updating:
|
-
Change to section 6.3 - Shelf life
|
|
Updated on 24/06/2004 and displayed until 17/12/2004
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for use
-
Change to section 4.2 - Posology and method of administration
|
|
Updated on 12/03/2004 and displayed until 24/06/2004
|
Reasons for adding or updating:
|
-
Change to section 2 - Qualitative and quantitative composition
-
Change to section 4.4 - Special warnings and precautions for use
-
Change to section 6.1 - List of excipients
|
|
Updated on 19/06/2003 and displayed until 12/03/2004
|
Reasons for adding or updating:
|
|
|
|